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Background: It has been suggested that there is an increase in aortic regurgitation (AR) in the short and medium
term after percutaneous closure of patent foramen ovale (PFO). The aim of this study is to determine the long-
term effect of percutaneous closure of PFO on the prevalence of AR.
Methods: Patients with cryptogenic stroke or transient ischemic attackwho had undergone percutaneous closure
of PFO more than ﬁve years before the study were invited to an echocardiographic examination.
Results: Out of 83 invited patients, 64 accepted the invitation and were examined with echocardiography. Mild
AR was found in one patient (2%), but this was already evident in the patient's echocardiographic result before
PFO closure. Trace ARwas detected in 11 patients (17%). No case ofmoderate or severe ARwas detected. Patients
with AR were more often hypertensive (six out of 12 patients with AR, compared to nine of the 52 without
AR, p = 0.025), and the indexed sinus of Valsalva was larger in patients with AR (18.6 mm/m2, SD 1.6, as
compared to 17.3 mm/m2, SD 1.6, p = 0.02).
Conclusion: In this long-term study with a minimum follow-up of 5.6 years and a mean of 7.1 years, we found
negligible levels of AR. Where present, AR was associated with hypertension and mild dilatation of the aortic
root, but there was no indication that device closure per se increased the risk of developing AR.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Patent foramen ovale (PFO) is associated with cryptogenic stroke,
and non-randomized studies suggest a reduction in stroke recurrence
after percutaneous closure [1–4]. In contrast, randomized trials showed
no signiﬁcant reduction in primary endpoints [5–7], but a secondary
per-protocol analysis of the RESPECT trial suggested a beneﬁt of PFO
closure [6]. Nonetheless, many patients in recent years have received
an occluder as a prophylactic measure after cryptogenic stroke. Short-
and medium-term follow-ups show a low risk, about 1%, of serious
adverse events, such as atrial perforation and thrombus formation on
the device [3,8]. An increased prevalence of aortic regurgitation (AR)
has also been reported [9,10]. Echocardiography up to one year after
closure showed a 10% increase in new or worsened AR, of which 92%edicine (251491), and by grants
cal Physiology, Sahlgrenska
teborg, Sweden. Tel.: +46 31
C. Johansson).
eliability and freedom from bias
nd Ltd. This is an open access article unweremild AR and 8%weremoderate AR. However, the long-termeffects
of closure are not known. Therefore,we performed an echocardiographic
follow-up, focusing on the presence or absence of AR at a mean of
7.1 years after percutaneous closure of PFO.
2. Methods
Between 1997 and 2006, 85 patients underwent percutaneous clo-
sure of a PFO at Sahlgrenska University Hospital/Östra, Gothenburg,
Sweden. An Amplatzer occluder (AGA Medical Corporation, MN, USA)
was used in all patients and the size and model of device was chosen
after balloon sizing. In 82 patients, a 25 or 35 mm Amplatzer PFO
occluder was used. It has a thin waist and the right atrial disk diameter
is the full size of the occluder. To ensure a better ﬁt, the left atrial disk
diameter is smaller, 18 or 25 mm. The Amplatzer atrial septal defect
(ASD) occluder, with a waist diameter corresponding to the stretched
balloon diameter of the defect, was used in three patients.
The following indications for PFO closurewere applied: (1) ﬁrst-ever
cryptogenic stroke or transient ischemic attack combinedwithhigh-risk
morphology, such as atrial septal aneurysm, or (2) PFO with low-risk
morphology in patientswith recurrent cryptogenic stroke or TIA events.
A single event was not considered to be an indication for closure of a
PFO with low-risk morphology [3]. The diagnosis of cryptogenic strokeder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Aortic regurgitation at baseline and at long-term follow-up.
Aortic regurgitation Baseline
n = 64
Long-term follow-up
n = 64
None, n (%) 56 (87) 52 (81)
Trace, n (%) 7 (11) 11 (17)
Mild, n (%) 1 (1.6) 1 (1.6)
Moderate or severe, n 0 0
Any AR, n (%) 8 (13) 12 (19)
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in stroke medicine. The majority of patients were referred by
neurologists. During this time period, the closure decision was made
by the interventional cardiologist. Atrial septal aneurysm was deﬁned
as at least 10mmbulging into one of the atria, beyond the plane of atrial
septum secundum [11]. All PFOs were diagnosed with contrast
transesophageal echocardiography before catheterization [12,13]. The
characteristics of the total population at the time of closure are shown
in Table 1. Hypertension was deﬁned according to medical treatment
for hypertension at follow-up. One patient with moderate carotid
stenosis suffered cortical blindness deemed as cryptogenic stroke, due
to splinter thrombosis, since CT showed bilateral infarction.
2.1. Echocardiography
A standard transthoracic echocardiogramwas performed with com-
mercially available echo machines (Vivid 7 or Vivid 9, General Electric,
Fairﬁeld, CT, USA). Special attention was paid to visualizing any AR,
thrombus formation on the device, atrial erosion or interatrial shunting.
Color Doppler imaging of the aortic valve was performed in the
parasternal long and short axis and in apical ﬁve-chamber and long-
axis views. In apical views, continuous and pulsed wave Doppler was
also registered. Classiﬁcation of aortic regurgitation was analyzed inde-
pendently by two physicians on ofﬂine images, using the EchoPAC PC
software (General Electric), and disparities were settled by consensus.
Investigatorswere blinded to clinical information, size andmodel of de-
vice, and to the degree of AR before closure. AR was classiﬁed as mild,
moderate, or severe, according to recent guidelines [14]. In addition,
trace AR was deﬁned as any visible regurgitation with a color Doppler
vena contracta less than 1 mm. Mild AR was deﬁned as vena contracta
at least 1 mm but less than 3 mm. The aortic root diameters were
measured by MJ according to guidelines [15] and indexed for body
surface area [16]. Pre-closure echocardiographic images and reports
from patients with any AR at follow-up were used to establish the
presence or absence of AR before closure. When the cusp morphology
was ambiguous on the transthoracic images, the transesophageal
images during closure and sixmonths after closurewere used to classify
the valve as tricuspid or not tricuspid.
The study was approved by the human research regional ethical
review board in Gothenburg and all patients gave written informed
consent. The patients received reimbursement only for travel expenses.
2.2. Statistics
The independent-samples t test was used for comparing age and
sinus Valsalva diameter in relation to AR and for comparing sinus
Valsalva diameter in relation to hypertension. For the analysis of hyper-
tension, atrial septal aneurysm and age groups in relation to AR, Fisher's
exact testwas used. The PFO 35mmoccluderwas comparedwith all the
other sizes combined in relation to AR and in relation to atrial septal an-
eurysm with Fisher's exact test. The baseline and follow-up prevalence
of any AR were compared with McNemar's test. A p-value b 0.05 wasTable 1
Population characteristics at the time of PFO closure.
Characteristics
Number of patients 85
Men, n (%) 47 (55)
Age in years, mean (SD) 48.7 (10.7)
BMI, kg/m2, mean (SD) 26.3 (6.3)
Current smoker or ex-smoker, n (%) 18 (21)
Hypertension, n (%) 14 (17)
Diabetes, n (%) 2 (2)
Hyperlipidemia, n (%) 15 (18)
Carotid stenosis N50%, n (%) 1 (1)
Atrial septal aneurysm, n (%) 58 (68)considered signiﬁcant and tests were two-sided. The inter-observer
variability of the presence/absence of AR was assessed in all follow-up
patients. The intra-observer reproducibility of aortic sinus diameter
measurements was assessed in 30 patients with the intraclass correla-
tion coefﬁcient (ICC). All statistical analyses were performed with IBM
SPSS Statistics version 19 (Armonk, NY: IBM Corp., USA).3. Results
Information on survival was available for all 85 patients, of whom
twohad died, both from lung cancer.Medical recordswith clinical infor-
mation were available and were reviewed in all the other patients. Out
of 83 invited patients, 64 (77%) agreed to visit the clinic and undergo an
echocardiographic examination. Among the other 19 patients, 14 were
living far away and ﬁve patients could not attend our center and thus
were interviewed by telephone. The mean time from closure to
follow-up was 7.1 years, SD 1.5, with a minimum of 5.6 years andmax-
imum 12.4 years. The mean age at follow-up was 55.9 years, SD 10.0
(25–75). Information on survival and recurrent stroke or TIA has been
reported previously [17].
Some degree of AR was detected in 12 (19%) of the 64 examined
patients, as shown in Table 2. There were no patients with moderate
or severe AR. Of the 12 cases of AR, 11 (17%) were trace AR, and only
four (6%) of these cases represented new trace AR; the remaining pa-
tient (2%) hadmild AR that was also evident in the baseline echocardio-
graphic result. Thus, ARwas already present at baseline in eight (12%) of
the patients. Patients with AR showed three distinguishing features re-
garding morphology, hypertension and age (Table 3). First, the aortic
root diameter was larger at the level of sinus Valsalva but with the
same aortic annulus diameter; however, the magnitude of dilatation
was mild, with only one patient showing a diameter over the normal
limit of 21 mm/m2 body surface area [16]. Second, hypertension was
more common in patients with AR and the aortic sinus diameter was
slightly, but non-signiﬁcantly, larger in patients with hypertension at
follow-up, as compared to those without hypertension (18.2 mm/m2,
SD 1.9 vs. 17.4 mm/m2, SD 1.6, p = 0.19). Third, patients with AR
were older than those without AR, but the difference did not reach
statistical signiﬁcance; the youngest patient with AR was 44 years of
age, as shown in Fig. 1. There was a non-signiﬁcant trend toward
more frequent AR with the PFO 35 mm occluder than with the smaller
sizes; this occluder was more often used in the presence of atrial septal
aneurysm (36 out of 42 compared to 10 out of 21, p = 0.02).Table 3
Comparison of patient characteristics in relation to the presence/absence of aortic regurgi-
tation at long-term follow-up.
No AR
N = 52
AR
N = 12
p
Sinus Valsalva, mm/m2 BSA, mean ± SD 17.3 ± 1.6 18.6 ± 1.6 0.015
Age in years, mean ± SD 55.3 ± 10.4 59.8 ± 8.3 0.17
Hypertension, n (%) 9 (17) 6 (50) 0.025
Atrial septal aneurysm, n (%) 35 (67) 11 (92) 0.16
ASD occluder, n 2 0
PFO occluder 25 mm, n 18 2
PFO occluder 35 mm, n 32 10 0.19*
Fig. 1. p N 0.2 for the comparison of AR prevalence according to age group. AR = aortic
regurgitation.
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patients. The devicewas visualized in the expected positionwithout any
signs of the device impinging on the aortic root. No residual shunt was
visualized with color Doppler. No serious adverse events e.g. pericardial
effusion, perforation or ﬁstulas occurred during the procedure or at
long-term. There was agreement between observers regarding the
presence/absence of AR in all but one of the follow-up exams and this
was resolved by consensus, corresponding to an inter-observer
reproducibility of 98.4%. The intra-observer reproducibility for aortic
sinus diameter was excellent (ICC = 0.952).4. Discussion
In this long-term follow-up study ofmore than seven years after PFO
closure, no patients with signiﬁcant AR were found. The mild AR that
was found in one patient (2%) was already evident before closure. A
distinguishing feature of the current study is that the follow-up time is
longer than in other studies. The current study thus adds new informa-
tion on the long-term safety of percutaneous closure of PFO. Our results
are in contrast with some other studies reporting on new AR after
closure [9,10], as shown in Table 4, where we compare details of the
other studies. The study that reported asmuch as 10% new or worsened
AR used the Cardia device in 98% of PFOs [9], and this device is no longerTable 4
Studies reporting aortic regurgitation after percutaneous closure of interatrial shunts.
Sadiq [27] Schoen [9] Loar
Type, no. of patients ASD, 205 PFO, 170
ASD, 70
PFO,
ASD,
Population Children and adults Adults Child
Follow-up time (range) 5.2 years
(6 months–10.3 years)
1 year 1.2 y
(2 m
Device (% of PFOs) Amplatzer ASD, 100% Cardia, 98%
Amplatzer, 2%
Ampl
Helex
Method TTE TEE
Trace AR reported as AR
TTE/T
Trace
Conclusion New AR in 1%, thought to be
due to oversizing of the device
New or worsened AR in 10%
of patients
New
patiein use. In the current study, the Amplatzer occluder was exclusively
used. The Amplatzer ASD occluder has a self-centeringwaist that should
correspond to the balloon-sized diameter of the defect.When oversized,
it overstretches the defect andmay thereby predispose to AR [10]. There
is also another model of the Amplatzer ASD occluder: the Amplatzer
multi-fenestrated “cribriform” occluder, thus named because it is
designed to cover multiple small defects in one location. It has a thin
waist and the two disks have the same diameter. Both these models
are designed for ASD closure and approved for use in the USA. In the
current study, on the other hand, the Amplatzer PFO 25 or 35 mm
occluder was used in 97% of the patients. Like the cribriform occluder,
it has a thin waist, but the diameter of the left atrial disk is smaller:
18 and 25mm. In our experience, thismakes the left side of the occluder
fall into place abutting on the aorta. The disks will be positioned closer
and more parallel to each other, instead of straddling the aorta, which
often happens with the cribriform occluder.
Trace AR was found in 11 of 64 patients, 17%. However, trace AR in a
morphologically normal valve is considered to be within the normal
range for the age group in this study. A large population survey in the
age range 40–60 years found AR in 6.2% of a healthy population [18].
The population survey also showed an increase with age, from 3.8% in
the age range 40–49 years to 8.1% in 50–59 year olds. Therefore, due
to normal aging during the average follow-up period of 7.1 years in
our study group, there ought to be about two new cases of AR at
follow-up. The Doppler technique is highly sensitive to small leakages,
so these regurgitations may be only a few milliliters [19]. In a recent
follow-up study after percutaneous closure, the presence of trace AR
was not regarded as AR [20]. With this approach, the current study
thus shows AR in only one patient (2%) and no new AR after closure. In
concordance with our results, a magnetic resonance imaging study
found no signiﬁcant difference in AR before versus after PFO closure
[21]. With that technique, the volume of backward ﬂow in the aorta
was calculated to be 1.9 ml (0.9–3.6) before closure and 2.9 ml
(1.5–4.1) (p = 0.108) after closure, but the presence of trace AR might
have beenmissed. A striking feature of two recent studies on PFO closure
is a high prevalence of AR before closure, 19% and 16%, most of which
was mild [9,10]. Another novel ﬁnding of our study is the relation be-
tween dilatation of the aortic root and the presence of AR. Dilatation of
the aortic root, often associated with increasing age and hypertension,
will predispose to both AR [22] and more aneurysmatic atrial septum
[23–25]. A wide aortic root may induce tenting of the aortic valve,
which reduces the area of coaptation between the cusps and predisposes
for regurgitation [26]. In general, dilatation of the aortic root will also
shorten the distance between the aortic wall and the atrial free wall,
which is the distance covered by the atrial septum. Any reduction in
this distancewill thusmake the atrial septum redundant andmore likely
to be aneurysmatic [24]. In the presence of a PFO, increased septalmobil-
ity is associated with increased right-to-left shunting [3]. A recent study
showed aortic sinus of Valsalva diameter to be larger in PFO patients
with cryptogenic cerebrovascular events, as compared to healthy
controls (34 mm, SD 4 versus 31 mm, SD 3) [25].[20] Wohrle [21] Krasniqi [10]
204
118
PFO, 102 PFO, 177
ren and adults Adults Adults
ears
onths–5 years)
1 year 6 months
atzer, 88%
, 12%
Cardia, 63%, Premere,
1% Amplatzer, 36%
Amplatzer, 100%
EE
AR reported as no AR.
MRI
Regurgitant volume and fraction
TTE/TEE
Trace AR reported as AR
mild AR in 0.6% of
nts
No change in regurgitation
volume
New or worsened AR in 9%
of patients
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In this single center study, the Amplatzer occluder was used in all
patients, so other brands were not tested. All the patients were selected
for closure and there was no non-closed control group. The follow-up
examination was not performed in 23% of study participants. There
are also some obvious limitations regarding the analysis of pre-closure
images, since this is a retrospective analysis; the baseline AR prevalence
might therefore be underestimated.
6. Conclusion
In this long-term study with follow-up of a minimum of 5.6 years
and a mean of 7.1 years, mild AR was found in 2% of patients but was
already evident before PFO closure. No moderate or severe AR was
found. Trace AR was seen in 17% of patients and the presence of AR
was associated with hypertension and mild dilatation of the aortic
root. There was no indication that device closure per se increased the
risk of developing AR.
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